Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2005
10/05/2005CN1678572A Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
10/05/2005CN1678372A Heterocyclic aromatic compounds useful as growth hormone secretagogues
10/05/2005CN1678334A New plant based agents as bioavailability/bioefficacy enhancers for drugs and nutraceuticals
10/05/2005CN1678325A Sapogenin derivatives, their synthesis and use and method based upon the use
10/05/2005CN1678320A N-biarylmethyl aminocycloalkanecarboxamide derivatives
10/05/2005CN1678317A 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(NK-1) antagonists for the treatment of emesis, depression, anxiety and cough
10/05/2005CN1678314A Glycinamide derivatives as raf-kinase inhibitors
10/05/2005CN1678311A Aryl carbonyl derivatives as therapeutic agents
10/05/2005CN1678203A Novel nutraceutical compositions comprising biotin
10/05/2005CN1676164A Colon positioned-release oral insulin self-micro emulsion formulation and capsule containing it
10/05/2005CN1676163A Human glucagon-like peptide-1 compound and its preparing method
10/05/2005CN1676131A Composition for treating hyperlipemia
10/05/2005CN1221546C Diphenyl azetidinone derivatives, method for prodn. thereof, medicaments contg. these compounds, and their use
10/05/2005CN1221535C Spiroimidazolidine derivatives, their prepn. their use and pharmaceutical preparation comprising them
10/05/2005CN1221284C Medicine for treating diabetes
10/05/2005CN1221273C Medication composition for treating diabetes
10/05/2005CN1221268C Magnesium-calcium ion composite preparation and production process thereof
10/05/2005CN1221262C Phthalazine derivatives for treating inflammatory diseases
10/05/2005CN1221258C Application of bendazac lysine in the preparing process of medicine for preventing and treating diabetic nephropathy
10/05/2005CN1221254C New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation
10/05/2005CN1221237C Composition for treatment of scars skin disease
10/05/2005CN1221182C Synanthrin products with improved nutritional properties
10/04/2005US6951938 Aryl fused azapolycyclic compounds
10/04/2005US6951916 Melanocortin receptor ligands
10/04/2005US6951890 Preventing and/or treating cardiovascular disease and/or associated heart failure
10/04/2005US6951889 7-acetamidinyl derivatives
10/04/2005US6951884 Fluorobenzamides and uses thereof
10/04/2005US6951882 treating obesity or a sleep/wake disorder mediated by orexin-2; antagonists
10/04/2005US6951879 Heteroaromate OSC inhibitors
10/04/2005US6951877 Materials and methods for treating hypercholesterolemia
10/04/2005US6951874 Compounds
10/04/2005US6951871 Indole derivatives useful as histamine H3 antagonists
10/04/2005US6951856 Substituted pyrimidine-sulfonamide derivatives are used as endothelin receptor antagonists
10/04/2005US6951855 vascular damaging agents
10/04/2005US6951852 osteoarthritis; little to no intrinsic estrogenicity; antagonizes the effects of 17 beta -estradiol with minimal uterine stimulation; bone loss inhibitor
10/04/2005US6951850 Dipeptide derivatives
09/2005
09/30/2005CA2499791A1 Angptl4/fiaf as marker for ppardelta modulation
09/29/2005WO2005090574A1 Vascular endothelial growth inhibiting gene
09/29/2005WO2005090378A1 Ligands of the molecule fit (agt-121) and their pharmaceutical use
09/29/2005WO2005090340A1 Piperidine-1-carboxamide derivative
09/29/2005WO2005090332A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005WO2005090330A1 N-piperidine derivates as ccr3 modulators
09/29/2005WO2005090301A1 Crystalline form of atorvastatin hemi calcium
09/29/2005WO2005089785A1 Acerola leaf extract-containing blood sugar level increase inhibitor and age formation inhibitor, and food containing them
09/29/2005WO2005089783A1 Lipoprotein lipase activity inhibitor
09/29/2005WO2005089782A1 Process for producing fermented stevia solution, health drink for livestock and udder wasiing liquor for livestock
09/29/2005WO2005089776A1 Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
09/29/2005WO2005089740A1 Coenzyme q composition with long-term persistence in blood
09/29/2005WO2005089714A1 Emulsion stabilizer
09/29/2005WO2004105752A8 Substituted pyrrole derivatives as hmg-coa reductase inhibitors
09/29/2005US20050215640 HMB compositions and uses thereof
09/29/2005US20050215630 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
09/29/2005US20050215616 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol; treating vaginal and skin atrophy
09/29/2005US20050215609 Novel uses of prostaglandin d2, prostaglandin d2 agonist and prostaglandin d2 antagonist
09/29/2005US20050215607 Drug composition for prevention or inhibition of advance of diabetic complication
09/29/2005US20050215596 Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals
09/29/2005US20050215594 Diabetes, obesity, urogenital disorders, cardiovascular disorders, atherosclerosis; 4-[(2R)-2-(([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)methyl)-3,4-dihydro-2H-chromen-6-yl]benzoic acid for example
09/29/2005US20050215593 Kaposi's sarcoma; Crohn's disease
09/29/2005US20050215557 For therapy and prophylaxis of inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis or rheumatoid arthritis etc
09/29/2005US20050215553 For therapy and prophylaxis of cardiovascular, central nervous system, inflammatory, and bone diseases as well as infectious diseases and certain cancers
09/29/2005US20050215550 Pyrazole-derived kinase inhibitors and uses thereof
09/29/2005US20050215528 Gnrh agonist combination drugs
09/29/2005US20050215496 Preparation and diabetic use of Gibberellins
09/29/2005US20050215477 Treating agonist disorderssuch asd diabetes, obesity, heart dysfunctions, AIDS-related wasting, and kidney, neurological, whole body growth disorders by administering a crystal of an insulin-like growth factor-1 that diffracts x-ray radiation to produce a three-dimensional diffraction pattern
09/29/2005US20050215469 Reducing food intake; obesity; dietetics
09/29/2005US20050215467 Multimeric Apo A-I agonist compounds
09/29/2005US20050214903 O-superfamily conotoxin peptides
09/29/2005US20050214780 Using polymorphism in potassium channel interacting protein (KChIP1) as diagnostic indicator for pancreatic disorders
09/29/2005US20050214762 Receptor binding domains of leptin; proteolysis; fusion proteins
09/29/2005US20050214392 Treatments for immune systems disorders
09/29/2005US20050214385 Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia
09/29/2005US20050214384 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
09/29/2005US20050214361 Shell contains non-water-soluble light-shielding agent, with medicine encapsulated within
09/29/2005US20050214346 For reducing serum cholesterol by increasing high density lipoprotein concentration; hypercholesterolemia
09/29/2005US20050214334 Composition for topical substance delivery
09/29/2005US20050214291 Treatment method
09/29/2005US20050214269 Induction of beta cell differentiation in human cells
09/29/2005DE102004012068A1 Neue alkyl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel New alkyl-containing 5-Acylindolinone, their preparation and their use as medicaments
09/29/2005CA2562388A1 Emulsion-stabilized preparation
09/29/2005CA2560286A1 Substituted quinazoline or pyridopyrimidine derivative
09/29/2005CA2560282A1 Crystalline form of atorvastatin hemi calcium
09/29/2005CA2560242A1 Human obesity susceptibility genes encoding peptide hormones and uses thereof
09/29/2005CA2560174A1 Y4 selective receptor agonists for therapeutic interventions
09/29/2005CA2560166A1 Y2/y4 selective receptor agonists for therapeutic interventions
09/29/2005CA2559838A1 Y2 selective receptor agonists for therapeutic interventions
09/29/2005CA2559545A1 Tetra-cyclic carboline derivatives for inhibiting angiogenesis
09/29/2005CA2558568A1 Opioid receptor antagonists
09/29/2005CA2558058A1 N-piperidine derivates as ccr3 modulators
09/29/2005CA2558030A1 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
09/29/2005CA2558020A1 Use of renin inhibitors in therapy
09/29/2005CA2555363A1 Coenzyme q compositions persisting in blood
09/28/2005EP1580266A1 Screening method
09/28/2005EP1579872A1 Body weight gain inhibitor
09/28/2005EP1579871A1 Vascular endothelial cell growth factor antagonists and uses thereof
09/28/2005EP1579868A2 Use of IL-11 for treating various diseases
09/28/2005EP1578914A2 Human ion channels
09/28/2005EP1578912A2 Il-13 mutein proteins, antibodies, compositions, methods and uses
09/28/2005EP1578902A2 Neurotransmission-associated proteins
09/28/2005EP1578897A2 Process for inducing functional tolerance to gene transfer products
09/28/2005EP1578798A1 Ghrelin receptor inverse agonist for regulation of feeding behaviours
1 ... 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 ... 1298